Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LQDA NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLQDALiquidia Technologies$23.22-4.2%$24.86$9.71▼$29.94$2.00B0.151.95 million shs1.96 million shsUTHRUnited Therapeutics$440.00-1.2%$369.35$266.98▼$459.48$19.85B0.66595,415 shs671,517 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLQDALiquidia Technologies+0.71%+10.73%-12.77%+72.11%+118.47%UTHRUnited Therapeutics-0.79%+0.44%+10.30%+50.71%+24.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLQDALiquidia Technologies$23.22-4.2%$24.86$9.71▼$29.94$2.00B0.151.95 million shs1.96 million shsUTHRUnited Therapeutics$440.00-1.2%$369.35$266.98▼$459.48$19.85B0.66595,415 shs671,517 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLQDALiquidia Technologies+0.71%+10.73%-12.77%+72.11%+118.47%UTHRUnited Therapeutics-0.79%+0.44%+10.30%+50.71%+24.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLQDALiquidia Technologies 2.70Moderate Buy$32.3839.43% UpsideUTHRUnited Therapeutics 2.67Moderate Buy$457.213.91% UpsideCurrent Analyst Ratings BreakdownLatest UTHR and LQDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025UTHRUnited TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$328.00 ➝ $435.0010/8/2025LQDALiquidia TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025UTHRUnited TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)10/6/2025LQDALiquidia TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.009/29/2025UTHRUnited TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$560.00 ➝ $580.009/27/2025LQDALiquidia TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025UTHRUnited TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)9/26/2025UTHRUnited TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$569.009/10/2025UTHRUnited TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$405.00 ➝ $525.009/5/2025UTHRUnited TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$510.00 ➝ $575.009/5/2025UTHRUnited TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$400.00 ➝ $500.00(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLQDALiquidia Technologies$19.32M103.46N/AN/A$0.91 per share25.52UTHRUnited Therapeutics$2.88B6.90$27.83 per share15.81$144.34 per share3.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLQDALiquidia Technologies-$130.39M-$1.70N/AN/AN/A-732.17%-232.96%-60.81%11/12/2025 (Estimated)UTHRUnited Therapeutics$1.20B$25.6217.1716.016.8440.36%18.73%16.49%10/29/2025 (Estimated)Latest UTHR and LQDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/29/2025Q3 2025UTHRUnited Therapeutics$6.75N/AN/AN/A$812.87 millionN/A8/12/2025Q2 2025LQDALiquidia Technologies-$0.43-$0.49-$0.06-$0.49$3.90 million$8.84 million7/30/2025Q2 2025UTHRUnited Therapeutics$6.80$6.41-$0.39$6.41$802.13 million$798.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLQDALiquidia TechnologiesN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLQDALiquidia Technologies9.842.492.41UTHRUnited TherapeuticsN/A7.266.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLQDALiquidia Technologies64.54%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipLQDALiquidia Technologies26.50%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLQDALiquidia Technologies5086.09 million63.28 millionOptionableUTHRUnited Therapeutics1,30545.11 million40.46 millionOptionableUTHR and LQDA HeadlinesRecent News About These CompaniesUnited Therapeutics price target raised to $435 from $328 at Morgan Stanley5 hours ago | msn.comUnited Therapeutics (NASDAQ:UTHR) Earns Hold (C+) Rating from Weiss RatingsOctober 9 at 9:33 PM | marketbeat.comMartine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) StockOctober 9 at 6:40 PM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Sells $1,803,440.00 in StockOctober 9 at 5:34 AM | insidertrades.comUnited Therapeutics (NASDAQ:UTHR) Sets New 52-Week High - Here's What HappenedOctober 8 at 5:56 AM | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of StockOctober 7 at 6:47 PM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Sells $1,798,760.00 in StockOctober 7 at 4:14 AM | insidertrades.comQRG Capital Management Inc. Raises Stock Position in United Therapeutics Corporation $UTHROctober 6, 2025 | marketbeat.comPolaris Capital Management LLC Reduces Stock Position in United Therapeutics Corporation $UTHROctober 4, 2025 | marketbeat.comHilltop National Bank Takes $341,000 Position in United Therapeutics Corporation $UTHROctober 4, 2025 | marketbeat.comHow Investors Are Reacting To United Therapeutics (UTHR) Positive Phase 3 Results for Tyvaso in IPFOctober 3, 2025 | finance.yahoo.comUnited Therapeutics (NASDAQ:UTHR) CEO Sells $1,739,520.00 in StockOctober 3, 2025 | insidertrades.comLecap Asset Management Ltd. Takes $667,000 Position in United Therapeutics Corporation $UTHROctober 3, 2025 | marketbeat.comRobeco Institutional Asset Management B.V. Boosts Stake in United Therapeutics Corporation $UTHROctober 3, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 SharesOctober 2, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) EVP Sells $4,802,600.00 in StockOctober 2, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Sets New 1-Year High - Still a Buy?October 2, 2025 | marketbeat.comBuy Rating for United Therapeutics Driven by Legal Positioning and Market Advantages Amid Patent LitigationOctober 2, 2025 | tipranks.comUnited Therapeutics (NASDAQ:UTHR) CEO Sells $1,702,520.00 in StockOctober 2, 2025 | insidertrades.comA Look Back at Therapeutics Stocks’ Q2 Earnings: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The PackOctober 2, 2025 | msn.comMichael Benkowitz Sells 22,500 Shares of United Therapeutics (NASDAQ:UTHR) StockOctober 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUTHR and LQDA Company DescriptionsLiquidia Technologies NASDAQ:LQDA$23.22 -1.03 (-4.25%) Closing price 03:59 PM EasternExtended Trading$22.90 -0.32 (-1.40%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.United Therapeutics NASDAQ:UTHR$440.00 -5.38 (-1.21%) Closing price 04:00 PM EasternExtended Trading$429.29 -10.71 (-2.43%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
